Neovascular age-related macular degeneration (AMD) has undergone substantial break-
throughs in diagnostic as well as therapeutic respect, with optical coherence tomography …

Visual acuity is a key outcome measure in the treatment of neovascular age-related macular
degeneration (nAMD) using anti-vascular endothelial growth factor agents. Large variations …

Age-related macular degeneration is the main cause of irreversible vision in developed
countries, and intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are …

Purpose To investigate the association of all reported common polymorphisms in anti‐
vascular endothelial growth factor (VEGF) therapy response and to identify potential …

Purpose We sought to determine if specific genetic single nucleotide polymorphisms (SNPs)
influence vascular endothelial growth factor inhibition response to ranibizumab in …

To explore whether the complement factor H (CFH) polymorphism rs1061170/Y402H is
associated with responsiveness to antivascular endothelial growth factor (VEGF) agents in …

Purpose The recent introduction of anti-VEGF drugs has widely changed the prognosis of
exudative age-related macular degeneration (AMD), even if a variable percentage of …

Aims The purpose of this study is to investigate whether gene polymorphisms of the vascular
endothelial growth factor A (VEGF-A) and its receptor (VEGFR-2) have a pharmacogenetics …

We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF
treatment for exudative age-related macular degeneration (AMD) in a prospective cohort …

Anti-vascular endothelial growth factor (anti-VEGF) therapies for neovascular age-related
macular degeneration (nAMD) have proven efficacy at a study-population level, although …